Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
about
Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersBronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosaPseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentPseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors.Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa.Subcutaneous implant with etonogestrel (Implanon®) for catamenial exacerbations in a patient with cystic fibrosis: a case report.Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosaManagement of refractory Pseudomonas aeruginosa infection in cystic fibrosisPseudomonas aeruginosa: resistance to the maxEvidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis.A case of failed eradication of cystic fibrosis-related sinus colonisation by Pseudomonas aeruginosaA Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic FibrosisSystematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.Inhaled therapeutics for prevention and treatment of pneumoniaClinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis. A study on 1,790 patients from the Spanish Bronchiectasis Historical Registry.Combination of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics in the lungs of cystic fibrosis patients.Bacterial colonization and associated factors in patients with bronchiectasis.Treatment of Pseudomonas aeruginosa infection in critically ill patients.Mutational activation of the AmgRS two-component system in aminoglycoside-resistant Pseudomonas aeruginosa.Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.Single-use disposable dry powder inhalers for pulmonary drug delivery.Tobramycin for the treatment of bacterial pneumonia in children.Gaining the Upper Hand on Pulmonary Drug Delivery.Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.MexY-promoted aminoglycoside resistance in Pseudomonas aeruginosa: involvement of a putative proximal binding pocket in aminoglycoside recognition.Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers.Individual Patterns of Complexity in Cystic Fibrosis Lung Microbiota, Including Predator Bacteria, over a 1-Year PeriodPopulation structure and antimicrobial susceptibility of both nonpersistent and persistent Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.Oxidative stress induction of the MexXY multidrug efflux genes and promotion of aminoglycoside resistance development in Pseudomonas aeruginosaIn vivo attenuation and genetic evolution of a ST247-SCCmecI MRSA clone after 13 years of pathogenic bronchopulmonary colonization in a patient with cystic fibrosis: implications of the innate immune response.Prevalence of virulence genes among bulgarian nosocomial and cystic fibrosis isolates of pseudomonas aeruginosaSuboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis.Pulmonary radiographic findings in young children with cystic fibrosis.Proton Pump Inhibitor Use Is Associated With an Increased Frequency of Hospitalization in Patients With Cystic Fibrosis.Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease.
P2860
Q30403958-D534C619-CFA6-462D-BCD9-ECAC8E973ACDQ33676387-DB330F81-0BFC-40E8-90AA-443E49207A4AQ33701145-5D2CEAB6-5997-48F3-B8E2-7CABF2E98920Q33824149-A64E45E5-CFF0-4D1E-8A27-65175213E049Q33889496-05496D94-58B6-4B34-8D89-350CE022DD88Q34042263-8B819B43-94EA-453B-847F-D019D897A53CQ34386310-42CB123E-104F-41FB-AA11-FDC60C973B6AQ34469663-B72F7C7C-6886-478A-9052-CEB28311B218Q34509793-96DCFBCA-03CB-4514-BA27-5888C62F51C7Q35026630-E9BC87D8-8D7D-4689-ADD3-70D07F02B2B7Q35084559-B5FC0540-3DC4-4B80-8DC1-4634767C1F9CQ35426622-754DD558-F9E2-471F-AD3F-9408D93FE15FQ35800789-32F019CC-C263-4629-96F1-59185603E7FDQ35855673-56CCBAE8-830B-455A-B351-EFD3379C2831Q35878860-9D6BBE89-57B8-4461-98E2-E6B1335741ECQ35879111-9ECDF599-D29E-4BE8-85E4-9481D7D7F8DAQ35925366-7024BD42-AE76-4F42-9063-4BD6DDC1031AQ36380278-76C2CF4B-5049-40F3-97A1-669C1BD436FCQ36477037-60D704AF-4DB5-4DA0-B52D-ABE9362F230BQ36566090-F5A20B70-7D3B-4F48-B693-1CE8DBD439C8Q36607415-C5423E58-9B45-4C9C-B198-0ABF90351894Q36785893-87673E51-2AB9-4344-8904-303BAD68B15CQ36870716-8F5A146F-F874-4EE5-863F-BA9D503086E8Q37809879-5566D95D-FC50-4393-8835-D5578BA96C17Q37980230-721BFBB5-60DE-428A-AAF7-00C829156AA5Q38240156-E76B2A50-2535-4DD2-B7DA-3DD0CCF42798Q38741128-BE8151B7-A80A-47D7-AF82-147DBE9E74E8Q38873261-773C34ED-43B6-4289-80B5-6EE292CFB4D6Q38991210-90791D27-183A-4A3A-BBD5-31CDF86673F5Q41676206-4C0DBFBC-E46C-407D-926E-B2CB39004638Q41822095-2A6129AC-F4E6-4F2F-831D-802B07E487D6Q41841534-F2398CC3-95C4-4319-BA4D-EEE0B2ECD9E3Q42202102-855D5AD2-F569-4221-A3E8-EA400391F8FBQ42593927-2E5C521B-4024-4C5B-BEEA-5B6B94F5CDA5Q42790860-01AC295F-9AFF-4DEA-9016-34DEB145DC09Q42927531-3F2810EB-7040-40BE-99F8-F7A2F2552B4AQ44022490-7762B8C7-411E-4779-BC62-0D73F7E59E75Q44603594-D4965EB0-774D-4C26-AB63-BD07D96989E7Q46894129-DE39844F-6A49-47BF-8768-FC52AF8F4DEFQ49334378-849E8EF8-55DD-4262-9088-3CBC6141C5A1
P2860
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antimicrobial therapy for pulm ...... a in cystic fibrosis patients.
@ast
Antimicrobial therapy for pulm ...... a in cystic fibrosis patients.
@en
type
label
Antimicrobial therapy for pulm ...... a in cystic fibrosis patients.
@ast
Antimicrobial therapy for pulm ...... a in cystic fibrosis patients.
@en
prefLabel
Antimicrobial therapy for pulm ...... a in cystic fibrosis patients.
@ast
Antimicrobial therapy for pulm ...... a in cystic fibrosis patients.
@en
P2093
P1476
Antimicrobial therapy for pulm ...... sa in cystic fibrosis patients
@en
P2093
E García-Quetglas
J Honorato
Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient
P304
P356
10.1111/J.1469-0691.2005.01217.X
P577
2005-09-01T00:00:00Z